Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Aplastic Anemia: early-phase trial registry
9 of 24 indexed Aplastic Anemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #686 of 28,707 conditions by registered trial count.
24 US clinical trials · 9 currently recruiting · #686 of 28,707 conditions by registered trial count
Aplastic Anemia: 24 US clinical trials tracked, 9 recruiting.
Aplastic Anemia is the subject of 24 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 16 in Phase 1-2 (earlier-stage). The most active sponsor is National Heart, Lung, and Blood Institute (NHLBI), running 2 of these trials.
Enrollment posture brief
Registry condition aplastic-anemia
OPEN 9 | RECR 38% | LATE 1 | EARLY 16 | RANK #686 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute-graft-versus-host Disease (38% recruiting · 8 trials)
Aplastic Anemia lists 9 open slots (38% of 24 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Aplastic Anemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Aplastic Anemia is recruiting below its size-band peers.
9 of 24 indexed trials (37.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Aplastic Anemia trials is spread across many organizations.
National Heart, Lung, and Blood Institute (NHLBI) accounts for 2 of 24 trials (8.3%). 21 distinct sponsors appear on at least one study for this condition label.
-
Most Aplastic Anemia trials plan to enrol fewer than 100 people.
Median target enrolment is 30 among the 24 trials that report a genuine target (sentinel values excluded). 22 of those (91.7%) plan for fewer than 100 participants.
-
Aplastic Anemia research is mostly interventional.
21 interventional and 3 observational studies make up this index (87.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
24 total, page 1 of 1
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT01624805
Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors
Children's Hospital of Philadelphia
NCT05194397
Two Step Haplo With Radiation Conditioning
Thomas Jefferson University
NCT05031897
Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy
Washington University School of Medicine
NCT06689800
A Study of Emapalumab for Pediatric Aplastic Anemia
Memorial Sloan Kettering Cancer Center
NCT06430788
Umbilical Cord Blood Transplantation From Unrelated Donors
University of Rochester
NCT03016806
Haploidentical HCT for Severe Aplastic Anemia
St. Jude Children's Research Hospital
NCT04558736
Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia
Fred Hutchinson Cancer Center
NCT06752694
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06398457
Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita
Boston Children's Hospital
NCT01659606
Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study
Ohio State University Comprehensive Cancer Center
NCT05972577
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
M.D. Anderson Cancer Center
NCT03622788
Oral Manifestations of Aplastic Anemia
National Institute of Dental and Craniofacial Research (NIDCR)
NCT00006300
Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00004464
Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia
Masonic Cancer Center, University of Minnesota
NCT02162420
A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT
Phoenix Children's Hospital
NCT03176849
Stem Cell Factor Medication for Aplastic Anemia
National Heart, Lung, and Blood Institute (NHLBI)
NCT00001398
Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic Anemia
The Cleveland Clinic
NCT01231841
TPO-Mimetic Use in Children for Hematopoietic Failure
Anjali Sharathkumar
NCT04478227
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
Massachusetts General Hospital
NCT01758042
Phase II Study of Bone Marrow Transplantation Using Related Donors in Patients With Aplastic Anemia
National Center for Research Resources (NCRR)
NCT00004323
Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization
Jennifer Woyach
NCT04439006
Neuropsychological Effects of Immunosuppressive Treatment in Subjects With Aplastic Anemia
National Heart, Lung, and Blood Institute (NHLBI)
NCT00767650
Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies
Joanne Kurtzberg, MD
NCT00673114
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 10 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Aplastic Anemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Aplastic Anemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Aplastic Anemia page
24 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 9 Aplastic Anemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Heart, Lung, and Blood Institute (NHLBI) sponsors the most Aplastic Anemia trials on record, review their full trial history before evaluating a specific study. See National Heart, Lung, and Blood Institute (NHLBI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Aplastic Anemia condition card totals 24 registered trials; most-linked intervention Fludarabine; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.